Astellas Eyes Doubling Market Cap On Core, Focus Assets
Offsetting Xtandi Patent Cliff
Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.
You may also be interested in...
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.
In this week's podcast edition of Five Must-Know Things: a pioneering KRAS inhibitor approval; Organon’s CEO on the company’s plans; Astellas’s mid-term ambitions; trial disappointment for Novartis’s Beovu; and Indian plans for a pediatric COVID vaccine.
Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.